Guidance, NICE advice and quality standards in development | Guidance

Showing 111 to 120 of 441

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early-value assessment	Health technology evaluation	22 January 2026
Digital technologies for multidisciplinary weight management	Health technology evaluation	TBC
Digital technologies to support asthma self-management: early value assessment	Health technology evaluation	17 April 2026
Digital technologies to support smoking cessation in secondary care patients: early value assessment	Health technology evaluation	TBC
Domestic Abuse	NICE guideline	TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance	TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Technology appraisal guidance	TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]	Technology appraisal guidance	18 June 2026
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]	Technology appraisal guidance	23 July 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC